Polypharmacy and Clinically Significant Drug Interactions Among HIV-Infected Patients Receiving Antiretroviral Therapy

Hospital General Universitario Gregorio Marañon1,000 enrolled

Overview

This will be a cross-sectional population-based study carried out in the region of Madrid (6,468,322 inhabitants according to current census) to quantify the number of Co-meds in HIV-infected individuals on ART in the region of Madrid, categorized by age and gender, and to compare the number of Co-meds between the ART-treated population and HIV-uninfected population in the region of Madrid, categorized by age and gender.

Study Type

OBSERVATIONAL

Enrollment

1,000

Conditions

HIV

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * patients who picked-up Co-meds in the study period Exclusion Criteria: * NONE

Outcomes

Primary Outcomes

the number of Co-meds in HIV-infected individuals on ART

number of Co-meds in HIV-infected individuals on ART in the region of Madrid, categorized by age and gender.

Time frame: 6 months

number of Co-meds between the ART-treated population and HIV-uninfected

the number of Co-meds between the ART-treated population and HIV-uninfected population in the region of Madrid, categorized by age and gender.

Time frame: 6 months

prevalence of potential CSDIs between ARVs and Co-meds in ART-treated individuals

prevalence of potential CSDIs between ARVs and Co-meds in ART-treated individuals, with description of the types of harm expected from each different potential CSDIs identified

Time frame: 6 months

Central Contacts

Juan Berenguer, PhD

CONTACT

+34620038850 jbb4@me.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.